REVIEW PAPER
Interference RNA in immune-mediated oral diseases – minireview
Submission date: 2016-07-12
Acceptance date: 2016-08-16
Publication date: 2017-10-30
Cent Eur J Immunol 2017;42(3):301-304
KEYWORDS
ABSTRACT
Immune-mediated oral disorders are characterised by their chronicity, and some are refractory to treatment. Interference RNA (iRNA) has been implicated in the underlying mechanism of such immune-mediate oral and refractory inflammatory oral diseases. iRNA-based understanding of the mechanism in these diseases may help to produce non-invasive diagnostic methodologies and treatment modalities of such drug non-responsive diseases. Oral lesions in these immune-mediated diseases can precede the occurrence of lesions in other regions of the body. The early diagnosis and treatment of these drug non-responsive diseases might benefit the patient by reducing chronicity and probably even resolving the disease. This aim of the present minireview is to give an overview of the possible implications of iRNA on the pathogenesis, diagnosis, and treatments of immune-mediated and inflammatory oral diseases. The manuscript can form the framework for research on iRNA in these immune-mediated oral disorders.
REFERENCES (40)
1.
Fire A, Xu S, Montgomery MK, et al. (1998): Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
2.
Hui L, Muller F, George AC (2013): MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865.
3.
Tiemann K, Rossi JJ (2009): RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 1: 142-151.
4.
Ma J, Dong C, Ji C (2010): MicroRNA and drug resistance. Cancer Gene Therapy 17: 523-531.
5.
Ranganathan K, Sivasankar V (2014): MicroRNAs-biology and clinical applications. J Oral Maxillofac Pathol 18: 229-234.
6.
Carthew RW, Sontheimer EJ (2009): Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642-655.
7.
Femke S, Alessia B, Isabelle CK, et al. (2010): Hairpin RNA induces secondary small interfering RNA synthesis and silencing in trans in fission yeast. EMBO Rep 11: 112-118.
8.
Willkomm S, Restle T (2015): Conformational Dynamics of Ago-Mediated Silencing Processes. Int J Mol Sci 16: 14769-14785.
9.
Pecot CV, Calin GA, Coleman RL (2011): RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59-67.
10.
Kandhavelu M, Lammi C, Buccioni M, et al. (2009): Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens. J Bioinformatics Seq Anal 1: 31-40.
11.
Sienski G, Donertas D, Brennecke J (2012): Transcriptional silencing of transposons by Piwi and maelstrom and its impact on chromatin state and gene expression. Cell 151: 964-980.
12.
Hsueh-Yen K and Haifan L (2014): PIWI proteins and their interactors in piRNA biogenesis, germline development and gene expression. Natl Sci Rev 1: 205-218.
13.
Felekkis K, Touvana E, Stefanou C, et al. (2010): MicroRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 14: 236-240.
14.
Yi R, O’Carroll D, Pasolli HA, et al. (2006): Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs. Nat Genet 38: 356-362.
15.
Cheng AM, Byrom MW, Shelton J, et al. (2005): Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297.
16.
Yekta S, Tabin CJ. Bartel DP (2008): MicroRNAs in the Hox network: An apparent link to posterior prevalence. Nat Rev Genet 9: 789-796.
17.
Guo SQ, Lu J, Schlanger R, Zhang H, Wang JY (2010): MicroRNA miR-125a controls hematopoietic stem cell number. PNAS 107: 14229-14234.
18.
Hu YL, Fong S, Largman C, et al. (2010): HOXA9 regulates miR-155 in hematopoietic cells. Nucleic Acids Res 16: 5472-5478.
19.
Ryan MO’C, Dinesh SR, Aadel AC, et al. (2013): Physiological and pathological roles for microRNAs in the immune system. Immunol Rev 253: 112-128.
20.
Siyun X, Yongsheng X, Li L, et al. (2014): Three new shRNA expression vectors targeting the CYP3A4 coding sequence to inhibit its expression. Acta Pharm Sin B 4: 350-357.
21.
Patrick JP, Amy AC, Emily B, et al. (2002): Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16: 948-958.
22.
Cowan GM, Lockey RF (2014): Oral manifestations of allergic, infectious, and immune-mediated disease. J Allergy Clin Immunol Pract 2: 686-696.
23.
Bascones-Martínez A, García-García V, Meurman JH, et al. (2015): Immune-mediated diseases: what can be found in the oral cavity? Int J Dermatol 54: 258-270.
24.
Shamim T, Varghese VI, Shameena PM, et al. (2008): Pemphigus vulgaris in oral cavity: Clinical analysis of 71 cases. Med Oral Pathol Oral Cir Bucal 13: E622-E626.
25.
Nico MM, Fernandes JD, LourenÇo SV (2011): Oral lichen planus. An Bras Dermatol 86: 633-641.
26.
Li W, Zhao Y, Xu X, et al. (2015): Rebamipide suppresses TNF-α mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J 2015; 282: 2317-2326.
27.
Verma N, Chaudhury I, Kumar D, et al. (2009): Silencing of TNF-αlpha receptors coordinately suppresses TNF-αlpha expression through NF-kappaB activation blockade in THP-1 macrophage. FEBS Lett 583: 2968-2974.
28.
Li X, Li J, Yang Y, et al. (2013): Differential gene expression in peripheral blood T cells from patients with psoriasis, lichen planus, and atopic dermatitis. J Am Acad Dermatol 69: e235-e243.
29.
Dang J, Bian YQ, Sun JY, et al. (2013): MicroRNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 42: 315-321.
30.
Volker G, Jochen H, Yahya A, et al. (2013): Disease-Associated miRNA-mRNA Networks in Oral Lichen Planus. PLoS One 8: e63015.
31.
Lewkowicz N, Lewkowicz P, Dzitko K, et al. (2008): Dysfunction of CD4+CD25 high T regulatory cells in patients with recurrent aphthous stomatitis. J Oral Pathol Med 37: 454-461.
32.
Huang TT, Yen MC, Lin CC, et al. (2011): Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci 102: 2214-2220.
33.
Al-Hashimi (2001): The management of Sjögren’s syndrome in dental practice J Am Dent Assoc 132: 1409-1417.
34.
Bhanji RA, Eystathioy T, Chan EK, et al. (2007): Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 125: 247-256.
35.
Alevizos I, Alexander S, Turner RJ, et al. (2011): MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren’s syndrome. Arthritis Rheum 63: 535-544.
36.
Bektas M, Jolly PS, Berkowitz P, et al. (2013): A pathophysiologic role for epidermal growth factor receptor in pemphigus acantholysis. J. Biol. Chem 288: 9447-9456.
37.
Qiyan L, Michael SV, Keith LK (2012): MAPK Usage in Periodontal Disease Progression. J Signal Transduct 2012: 308943.
38.
Li Q, Yu H, Zinna R, Martin K, et al. (2011): Silencing MAP kinase-activated protein kinase-2 arrests inflammatory bone loss. J Pharmacol Exp Ther 336: 633-642.
39.
Dabra S, Chhina K, Soni N, et al. (2012): Tissue engineering in periodontal regeneration: A brief review. Dent Res J 96: 71-80.
40.
Ma J, Chen W, Zhang L, et al. (2013): RNA interference-mediated silencing of Atp6i prevents both periapical bone erosion and inflammation in the mouse model of endodontic disease. Infect Immun 81: 1021-1030.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
